摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5'-(aminomethyl)-5'-deoxy-2',3'-O-isopropylideneadenosine | 107961-53-5

中文名称
——
中文别名
——
英文名称
5'-(aminomethyl)-5'-deoxy-2',3'-O-isopropylideneadenosine
英文别名
2′,3′-O-isopropylidene-5′-deoxy-5′-aminomethyldenosine;9-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyltetrahydrofuro[3,4-d]-[1,3]dioxol-4-yl)-9H-purin-6-amine;9-((3aR,4R,6R,6aR)-6-(2-aminoethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine;9-[(3aR,4R,6R,6aR)-6-(2-aminoethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]purin-6-amine
5'-(aminomethyl)-5'-deoxy-2',3'-O-isopropylideneadenosine化学式
CAS
107961-53-5
化学式
C14H20N6O3
mdl
——
分子量
320.351
InChiKey
INPFNFFBBAUQLZ-QYVSTXNMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.17
  • 重原子数:
    23.0
  • 可旋转键数:
    3.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    123.33
  • 氢给体数:
    2.0
  • 氢受体数:
    9.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5'-(aminomethyl)-5'-deoxy-2',3'-O-isopropylideneadenosine 在 sodium hydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺三氟乙酸 作用下, 以 四氢呋喃二氯甲烷 、 mineral oil 为溶剂, 反应 35.0h, 生成 methyl 6-(3-(4-(3-(2-((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)ethyl)guanidino)butyl)ureido)-4-hydroxy-2-naphthoate
    参考文献:
    名称:
    通过解构-重建和片段生长方法将 I 型蛋白精氨酸甲基转移酶的非选择性抑制剂转化为蛋白精氨酸甲基转移酶 4 的有效和选择性抑制剂
    摘要:
    蛋白质精氨酸甲基转移酶 (PRMT) 是重要的治疗靶点,在许多细胞过程的调节中起着至关重要的作用,并与许多疾病有关。然而,关于它们的功能和它们所涉及的生物学途径,以及可能推动 PRMT 活性选择性调节剂发展的结构要求,仍有许多有待了解。在这里,我们报告了一种解构-重建方法,该方法从我们之前鉴定的一系列 I 型 PRMT 抑制剂开始,允许鉴定 PRMT4 的有效和选择性抑制剂,无论细胞渗透性低如何,都显示精氨酸甲基化明显减少MCF7 细胞中的水平和增殖的显着减少。
    DOI:
    10.1021/acs.jmedchem.2c00252
  • 作为产物:
    描述:
    tert-butyl (2-((4R,6R)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)ethyl)carbamate 在 三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 以65%的产率得到5'-(aminomethyl)-5'-deoxy-2',3'-O-isopropylideneadenosine
    参考文献:
    名称:
    通过解构-重建和片段生长方法将 I 型蛋白精氨酸甲基转移酶的非选择性抑制剂转化为蛋白精氨酸甲基转移酶 4 的有效和选择性抑制剂
    摘要:
    蛋白质精氨酸甲基转移酶 (PRMT) 是重要的治疗靶点,在许多细胞过程的调节中起着至关重要的作用,并与许多疾病有关。然而,关于它们的功能和它们所涉及的生物学途径,以及可能推动 PRMT 活性选择性调节剂发展的结构要求,仍有许多有待了解。在这里,我们报告了一种解构-重建方法,该方法从我们之前鉴定的一系列 I 型 PRMT 抑制剂开始,允许鉴定 PRMT4 的有效和选择性抑制剂,无论细胞渗透性低如何,都显示精氨酸甲基化明显减少MCF7 细胞中的水平和增殖的显着减少。
    DOI:
    10.1021/acs.jmedchem.2c00252
点击查看最新优质反应信息

文献信息

  • Synthesis and evaluation of protein arginine N-methyltransferase inhibitors designed to simultaneously occupy both substrate binding sites
    作者:Matthijs van Haren、Linda Quarles van Ufford、Ed E. Moret、Nathaniel I. Martin
    DOI:10.1039/c4ob01734j
    日期:——
    transferring a methyl group from the cofactor S-adenosyl-L-methionine (AdoMet) to the guanidine group of arginine residues in target proteins. The most notable is the PRMT-mediated methylation of arginine residues that are present in histone proteins which can lead to chromatin remodelling and influence gene transcription. A growing body of evidence now implicates dysregulated PRMT activity in a number of diseases
    蛋白质精酸N-甲基转移酶(PRMT)是一类酶,其作用是通过从辅助因子S-腺苷基L特异性转移甲基来发挥功能-甲酸(AdoMet)修饰靶蛋白中精酸残基的基。最值得注意的是组蛋白中存在的PRMT介导的精酸残基甲基化,可导致染色质重塑并影响基因转录。现在越来越多的证据表明PRMT活性失调可能导致多种疾病,包括各种形式的癌症。因此,PRMT抑制剂的开发可能具有开发新疗法的潜力。我们在此报告了一系列小分子PRMT抑制剂的合成和评估,这些抑制剂旨在同时占据基底物和AdoMet辅因子的结合位点。当针对一组甲基转移酶测试这些化合物时,观察到有效的抑制作用和令人惊讶的选择性。
  • Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity
    作者:Christian Lerner、Birgit Masjost、Armin Ruf、Volker Gramlich、Roland Jakob-Roetne、Gerhard Zürcher、Edilio Borroni、François Diederich
    DOI:10.1039/b208690p
    日期:——
    Inhibition of the enzyme catechol-O-methyltransferase (COMT) is an important approach in the treatment of Parkinson's disease. A series of new potent bisubstrate inhibitors for COMT, resulting from X-ray structure-based design and featuring adenosine and catechol moieties have been synthesised. Biological results show a large dependence of binding affinity on inhibitor preorganisation and the length of the linker between nucleoside and catechol moieties. The most potent bisubstrate inhibitor for COMT has an IC50 value of 9 nM. It exhibits competitive kinetics for the SAM and mixed inhibition kinetics for the catechol binding site. Its bisubstrate binding mode was confirmed by X-ray structure analysis of the ternary complex formed by the inhibitor, COMT and a Mg2+ ion.
    抑制儿茶酚-O-甲基转移酶(COMT)是治疗帕森病的重要方法。根据基于X射线结构设计的原理,一系列新型强效双底物COMT抑制剂已被合成,这些抑制剂具有腺苷儿茶酚结构单元。生物学结果显示,结合亲和力对抑制剂的预组织结构及核苷与儿茶酚单元间连接链的长度有较大依赖性。对COMT最有效的双底物抑制剂的IC50值为9 nM。它对SAM结合位点表现出竞争性动力学特性,而对儿茶酚结合位点则呈现出混合抑制动力学特征。其双底物结合模式通过分析抑制剂、COMT及Mg2+离子形成的三元复合物的X射线结构得到确认。
  • [EN] PROTEIN ARGININE N-METHYLTRANSFERASES INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DES PROTÉINE-ARGININE N-MÉTHYLTRANSFÉRASES ET LEURS UTILISATIONS
    申请人:PF MEDICAMENT
    公开号:WO2017211958A1
    公开(公告)日:2017-12-14
    The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use thereof as a drug, notably in the treatment of cancer, or as a PRMT inhibitor. The present invention relates also to a pharmaceutical composition containing such a compound and to a method for the preparation of such a compound.
    本发明涉及以下式(I)的化合物或其药用可接受的盐和/或溶剂,特别是用作药物,特别是用于癌症治疗,或作为PRMT抑制剂。本发明还涉及含有这种化合物的药物组合物以及制备这种化合物的方法。
  • Bisubstrate-Type Chemical Probes Identify GRP94 as a Potential Target of Cytosine-Containing Adenosine Analogs
    作者:Dany Pechalrieu、Fanny Assemat、Ludovic Halby、Marlene Marcellin、Pengrong Yan、Karima Chaoui、Sahil Sharma、Gabriela Chiosis、Odile Burlet-Schiltz、Paola B. Arimondo、Marie Lopez
    DOI:10.1021/acschembio.9b00965
    日期:2020.4.17
    We synthesized affinity-based chemical probes of cytosine-adenosine bisubstrate analogs and identified several potential targets by proteomic analysis. The validation of the proteomic analysis identified the chemical probe as a specific inhibitor of glucose-regulated protein 94 (GRP94), a potential drug target for several types of cancers. Therefore, as a result of the use of bisubstrate-type chemical
    我们合成了基于亲和力的化学探针的胞嘧啶-腺苷双底物类似物,并通过蛋白质组学分析确定了几个潜在的目标。蛋白质组学分析的有效性确定了该化学探针是葡萄糖调节蛋白94(GRP94)的特异性抑制剂,该蛋白是多种类型癌症的潜在药物靶标。因此,由于使用了双底物型化学探针和化学生物学方法,这项工作为开发可能具有治疗意义的新的GRP94抑制剂家族开辟了道路。
  • Isozyme-specific enzyme inhibitors. 13. S-[5'(R)-['N-triphosphoamino)methyl]adenosyl]-L-homocysteine, a potent inhibitor of rat methionine adenosyltransferases
    作者:Vivekananda M. Vrudhula、Francis Kappler、Alexander Hampton
    DOI:10.1021/jm00388a024
    日期:1987.5
    A synthesis is described of the title compound and its 5'S epimer, which are two-substrate adducts of adenosine 5'-triphosphate (ATP) and L-methionine (Met) in which the C(5')H2OP system in ATP is replaced by CH(R)CH2NHP [R = L-S(CH2)2CH(NH2)CO2H]. The 5'R epimer was a potent nonselective competitive inhibitor [averaged Ki = 0.32 microM; KM(ATP)/Ki = 440] vs. ATP of the rat M-2 (normal tissue) and M-T (Novikoff ascitic hepatoma) variants of methionine adenosyltransferase. It produced simple noncompetitive inhibition (averaged Ki = 2.7 microM) vs. Met with both variants. The 5'S epimer inhibited M-T competitively vs. ATP, but was 74-fold less effective than the 5'R epimer. Replacement of the homocysteine moiety in the 5'R epimer by hydrogen markedly reduced inhibitory potency, as indicated by Ki values of 14 microM for competitive inhibition vs. ATP and 580 microM for noncompetitive inhibition vs. Met with M-2. The data suggest that the 5'R epimer can interact simultaneously with two enzymic sites. Information on the kinetic mechanism of a human counterpart of M-2 and inhibitor properties of a previously studied Met-ATP adduct are consistent with the view that the two sites might resemble those that interact with the initial products of the reaction, S-adenosylmethionine and triphosphate.
查看更多